Previous 10 | Next 10 |
BOSTON, MA / ACCESSWIRE / June 21, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases and cancer indications, announced that partner Ast...
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory and cancer diseases, today announced that Stephen Yoder, p...
BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the pre...
BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the p...
2023-05-17 00:55:30 ET Summary Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate. Potential deals on PRS-220 and PRS-343 could bolster the Company's balance sheet. The Company's low...
2023-05-11 13:23:49 ET If you’re like most retail traders, you’re looking for ways to make money in the stock market today. With that, if you’re reading this article, it’s highly likely that you’re on the hunt for the best penny stocks to buy. In this ...
2023-05-10 11:03:07 ET Pieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Thomas Bures - CFO Stephen Yoder - President and CEO Shane Olwill - Chief Development Officer Conference Call Particip...
2023-05-10 07:11:28 ET Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q1 GAAP EPS of -$0.18 misses by $0.04 . Revenue of $1.94M (-82.3% Y/Y) misses by $4.57M . For further details see: Pieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, rev...
COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDT Enrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clinical data anticipated by mid-2024; successful safety review completed for 10 mg dose cohort...
2023-05-09 11:38:25 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, before market open. The consensus EPS Estimate is -$0.09 (-28.6% Y/Y) and the consensus Revenue Estimate is $6.51M (-40.8% Y/Y). Over the...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-04-23 09:02:03 ET Pieris Pharmaceuticals Inc (PIRS) announced stock split at a ratio of 1-for-80 on 2024-04-23 ... Full story available on KlickAnalytics.com
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Co...
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin ® (antibody-Anticalin fusion) protein immuno-oncolo...